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Background: MicroRNAs (miRNAs) are short non-coding RNAs involved in the posttranscriptional regulation of a
wide range of biological processes. By binding to complementary sequences on target messenger RNAs, they
trigger translational repression and degradation of the target, eventually resulting in reduced protein output.
MiRNA-dependent regulation of protein translation is a very widespread and evolutionarily conserved mechanism
of posttranscriptional control of gene expression. Accordingly, a high proportion of mammalian genes are likely
to be regulated by miRNAs. In the hematopoietic system, both transcriptional and posttranscriptional regulation
of gene expression ensure proper differentiation and function of stem cells, committed progenitors as well
as mature cells.
Results: In recent years, miRNA expression profiling of various cell types in the hematopoietic system, as well as
gene-targeting approaches to assess the function of individual miRNAs, revealed the importance of this type of
regulation in the development of both innate and acquired immunity.
Conclusions: We discuss the general role of miRNA biogenesis in the development of hematopoietic cells,
as well as specific functions of individual miRNAs in stem cells as well as in mature immune cells.
Keywords: Adaptive immunity, Development, Embryonic stem cells, Hematopoiesis, Hematopoietic stem cells,
Innate immunity, miRNAsReview
Introduction
The differentiation and homeostasis of the hematopoietic
system requires complex and interconnected molecular
networks that need to be carefully regulated. In fact, a
wide repertoire of different immune cells originates from
hematopoietic stem cells (HSCs) in the bone marrow, cells
characterized by multipotency and self-renewal capabil-
ities. These cells generate the whole range of mature cells
in the blood, whose functions also need to be tightly con-
trolled in order to avoid cellular responses from running
amok and becoming damaging for the organism. Both
transcriptional and posttranscriptional regulatory mecha-
nisms ensure proper cellular differentiation and function
through modulation of cell death, proliferation, activation
and lineage commitment. Among the regulatory factors
involved in these processes are microRNAs (miRNAs), a
class of short non-coding RNAs whose pivotal roles in* Correspondence: silvia.monticelli@irb.usi.ch
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article, unless otherwise stated.fine-tuning the hematopoietic system have emerged in the
past several years. The first groundbreaking study about a
role for miRNAs in the differentiation of the immune
system showed how forced expression of miR-181 in
hematopoietic progenitors markedly increased the
number of B lymphocytes, with a concomitant reduction
of T lymphocytes [1]. Since then, the role of miRNAs in
the immune system has been extensively studied and these
molecules were discovered to be critical regulators of both
normal immune functions as well as disease. Highlighting
the widespread conservation of this type of regulation of
gene expression, the miRBase database (www.mirbase.org)
lists a constantly increasing number of miRNAs expressed
in more than 200 different species [2]. In this review
we will provide a snapshot on the role of miRNAs
specifically during the development of immune cells
from hematopoietic progenitors.MicroRNAs
MiRNAs are small non-coding RNAs, usually 21–25 nu-
cleotides (nt) long, present in a wide variety of organisms
and able to regulate gene expression by targeting messen-
ger RNAs (mRNAs). Specifically, they act by binding totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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target mRNA, resulting in repression of translation and/or
degradation of the targeted molecule, either of which leads
eventually to gene silencing. MiRNA biogenesis involves
several steps: a long primary transcript (pri-miRNA) is
transcribed by a RNA polymerase (usually RNA polymer-
ase II) and is typically polyadenylated. The pri-miRNA
may contain one or more hairpins, as miRNAs can be
clustered together to give rise to polycistronic transcrip-
tional units [3]. In the nucleus, the hairpin is excised from
the pri-miRNA by the Microprocessor complex, minim-
ally composed by the RNAseIII Drosha and the double-
stranded RNA-binding protein DGCR8. The resulting
hairpin precursor (pre-miRNA) is usually 60–110 nt long,
and is actively exported to the cytoplasm by the nuclear-
membrane protein Exportin-5 [3]. In the cytoplasm,
another protein complex containing the RNAseIII enzyme
Dicer further processes the pre-miRNA to the mature
miRNA, which is loaded onto the RNA Induced Silencing
Complex (RISC). Only one of the two strands of the
original pre-miRNA stem remains bound to the RISC
(the guide strand) as mature miRNA, whereas the other
strand (passenger strand or miRNA*) may be eliminated.
Importantly, Drosha processing of the pri- to pre-miRNA
can be a cotranscriptional process that does not impair
splicing of the primary transcript [4,5]. This is particularly
important for those miRNAs that are transcribed within
introns of protein-coding genes, as miRNA processing
does not impair mRNA maturation, and protein synthesis
is therefore not affected by Drosha cleavage [5]. Besides
the canonical biogenesis of miRNAs outlined above, a
small portion of miRNA precursors named mirtrons
derive from spliced introns and do not require Drosha
activity for their maturation [6,7]. Once generated, the
RISC-miRNA complex recognizes its cognate binding
sites in the 3′UTR of target mRNAs to induce gene
silencing.
MicroRNAs in embryonic stem cells
Recent studies elucidated the role of miRNAs in the
regulation of the biological function of embryonic stem
(ES) cells, derived from the inner cell mass of blasto-
cysts. ES cells are characterized by self-renewal capabil-
ity and totipotency, features that allow these cells to
maintain their own identity throughout mitotic cell
division and to differentiate into the entire range of
specialized cell types required in a multicellular organism.
Totipotency is ensured by the expression of few transcrip-
tion factors such as Nanog, Oct4 and Sox2 [8-10]. Indeed,
ectopic expression of some of these factors (Oct3/4, Sox2,
c-Myc, and Klf4) is enough to reprogram differentiated
cells to a totipotent state [11]. A strong downregula-
tion of these markers together with the expression of
lineage-specific activators trigger ES cell differentiation inthe three primary germ layers (endoderm, ectoderm and
mesoderm). Importantly, the transcriptional regulation of
ES cell differentiation has been also associated with
changes in the miRNA expression profile [12-14]. The first
evidence that miRNAs were involved in regulating ES cell
biology came from studies in which miRNA biogenesis
was eliminated through deletion of the gene encoding for
Dicer (Dicer1). Genetic ablation of Dicer1 in mouse ES
cells resulted in morphological abnormalities in the early
stages of development and embryonic lethality [15]. Con-
sistently, Dicer-deficient ES cells expressed ES cell-specific
markers such as the short α6-integrin isoform and Oct4,
but failed to generate detectable teratomas upon subcuta-
neous injection into nude mice, and did not express any
of the most common differentiation markers for both the
mesodermal and endodermal lineages, such as T-Brachy-
ury, Gata1, Bmp4 and Hnf4, indicating that Dicer ablation
leads to defects in ES cell differentiation [16]. Another
important level of miRNA regulation in ES cells is related
to epigenetic modifications in the genome. Indeed, a
global reduction of DNA methylation was observed in
Dicer-deficient ES cells, which was associated with re-
duced centromeric silencing and affected telomere-length
homeostasis [16,17]. Moreover, reduced levels of de novo
methylation in ES cells in the absence of Dicer were asso-
ciated to downregulation of DNA methyltransferases with
a mechanism that was dependent on the expression of the
miR-290 miRNA cluster [17]. Consistently, the defects in
DNA methylation could be rescued by transfection of the
miR-290 cluster in Dicer-deficient ES cells, indicating that
de novo DNA methylation in ES cells is at least in part
controlled by miRNAs [18]. Another indication that miR-
NAs have a crucial role in ES cell biology came from
studies performed in the absence of the Dgcr8 gene, which
encodes for an essential component of the nuclear Micro-
processor complex [19]. Specifically, ES cells deficient for
DGCR8 lacked miRNA expression, and during differenti-
ation the main pluripotency markers Oct4, Sox2 and
Nanog could only partially be silenced. Moreover, cells
were severely impaired in their ability to express diffe-
rentiation markers for the three germ layers including
Fgf5, T-Brachyury and Hnf4a. In particular, Fgf5, a marker
of primitive ectoderm that was highly expressed in wild-
type embryoid bodies (EBs) from day 2 of differentiation,
could be detected only at day 8 in Dgcr8-deleted EBs and
never reached the levels of the control. Moreover, a block
in the G1-S transition during cell cycle progression was
observed in Dgcr8-deleted ES cells, and after injection in
immunocompromised mice these ES cells developed
undifferentiated teratomas, therefore confirming that
miRNAs are indeed fundamental for proper differentiation
of ES cells [19].
In the last decade, a role for miRNAs has become
evident not only in the maintenance of the “stemness”
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modulation of the expression of the master pluripotency
genes, but also during early organogenesis. For example,
using both gain- and loss-of-function approaches,
Krichevsky et al. demonstrated that the early overex-
pression of miR-124a in neural precursors prevented
gliogenesis, whereas miR-9 favored differentiation
into neurons [13]. Inhibition of miR-9 in neural precur-
sors led to reduced neuronal differentiation through
increased STAT3 phosphorylation, which is known to be
involved in the inhibition of neuronal differentiation
[20-22]. On the contrary, the concomitant overexpression
of both miR-124a and miR-9 repressed induction of the
STAT3 pathway preventing differentiation of the neural
precursors into astrocytes [13]. The small C-terminal
domain phosphatase 1 (SCP1) was also identified as a pri-
mary target for miR-124a in neurons, and SCP1 repression
mediated by miR-124 induced neuronal differentiation,
pointing towards a crucial role for this miRNA in regu-
lating signaling events that lead to neuron development
[23]. In another example of miRNA-dependent regulation
of differentiation to specific lineages, a role for miR-1 and
miR-133 was established for differentiation to cardiomyo-
cytes: both of these miRNAs were enriched in cardio-
myocytes derived from ES cells at the early stages of
cardiac mesoderm selection, but they were repressed in
the ectodermal and endodermal lineages [14]. However,
these two miRNAs showed opposing behaviors during
further differentiation into the muscle lineage, since
miR-1 promoted and miR-133 blocked the differentiation
into cardiac progenitors or skeletal myoblasts [14].
Confirming the fact that miR-1 is an essential regulator of
cardiogenesis, deletion of miR-1-2 in mice revealed dys-
functions in cardiac morphogenesis, electrical conduction
and cell cycle control [24].
Hematopoietic differentiation
A properly regulated hematopoietic differentiation is
essential throughout the life of an organism to form all
blood cells required for gas exchange, wound healing
and for an appropriate defense from invading pathogens.
During embryonic development, hematopoiesis takes
place at first in the yolk sac, then the placenta and major
arteries become also involved, followed by the fetal liver
and finally the bone marrow [25,26]. In the adult, bone
marrow-resident stem cells can be mainly subdivided
into two defined subsets: long-term reconstituting
HSCs (LT-HSCs) and short-term reconstituting HSCs
(ST-HSCs). LT-HSCs maintain their self-renewal and
multi-lineage differentiation potential throughout the
entire life of the organism and give rise to ST-HSCs,
which are instead more limited in terms of self-renewal
capability, although they maintain multipotency and are
able to differentiate into multipotent progenitors (MPPs)[27] (Figure 1). Although a few different markers can
identify various subpopulations of stem cells, for the most
part the cell hierarchies within the HSC population can be
defined by the differential expression of the following
surface markers: Sca-1, c-Kit, CD135, CD48, CD150 and
CD34. LT-HSCs are characterized by the total absence of
lineage specific markers on the surface (“lineage negative”
or Lin– cells), and by the expression of Sca-1, c-Kit and
CD150. When LT-HSCs differentiate into ST-HSCs, they
progressively express CD34, followed by CD48 expression
in MPPs [28]. Distinct populations of MPPs generate
lineage-committed oligopotent progenitors including the
common lymphoid progenitor (CLP), common myeloid
progenitor (CMP), megakaryocyte-erytrocyte progenitor
(MEP) and granulocyte-monocyte progenitor (GMP).
Lineage committed progenitors, in turn, give rise to
mature cells including B, T and NK cells, granulocytes,
monocyte/macrophages, mast cells and megakaryocytes.
Flow cytometric analysis allows the discrimination of the
myeloid and lymphoid lineages based on the downregula-
tion of CD150 and the acquisition of CD135 markers,
respectively [28]. Overall, the entire hematopoietic system
is organized as a tree where the developmental potential is
restricted in each branch point: each step is tightly regu-
lated by environmental signals from the niche, signaling
molecules, specific transcription factors as well as miR-
NAs [27]. Representative examples of miRNAs involved in
hematopoietic differentiation are discussed in the follow-
ing paragraphs, and are summarized in Figure 1.
The role of miRNAs in maintaining stemness and favor
HSC differentiation
The importance of miRNAs in regulating the state of
HSCs in the hematopoietic system was shown upon
ablation of Dicer specifically in the hematopoietic stem/
progenitor compartment, which resulted in loss of
functional HSCs due to increased apoptosis [29]. Inter-
estingly, a single miRNA, miR-125a, was found to be
sufficient to modulate HSC self-renewal and numbers,
and to protect Lin– progenitor cells from apoptosis [29].
Similarly to what has been described for ES cells, differ-
ent families of miRNAs regulate HSC self-renewal and
differentiation capabilities, and HSCs are characterized
by a specific miRNA signature in each state of differenti-
ation. For example, LT-HSCs showed enriched expres-
sion of a group of miRNAs that included miR-125a,
miR-125b, miR-155, miR-99a, miR-126, miR-196b,
miR-130a, miR-542-5p, miR-181c, miR-193b and let7e
[30]. In order to assess their impact on long-term
hematopoietic engraftment, these miRNAs were over-
expressed through retroviral transduction in bone marrow
cells and injected into lethally irradiated recipients.
Depending on the miRNA overexpressed, different phe-
notypes emerged in the hematopoietic compartment.
Figure 1 Schematic representation of the hematopoietic system with some of the miRNAs involved in its regulation. MiRNAs that block
a specific stage are indicated in grey, whereas miRNAs that promote development are indicated in black. LT-HSC: long-term hematopoietic stem
cell; ST-HSC: short-term hematopoietic stem cell; MPP: multipotent progenitors; CMP: common myeloid progenitor; CLP: common lymphoid
progenitor; MEP: megakaryocyte-erythroid progenitor; GMP: granulocyte-macrophage progenitor; ErP: erythroid progenitor; MKP: megakaryocyte
progenitor; RBC: red blood cells.
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conferred a competitive advantage to the engrafted
bone marrow, whereas miR-196b, miR-181c, let7e and
miR-542-5p caused a significant disadvantage. In all
cases, the effects of the engraftment were observed
on all downstream lineages, suggesting that these miRNAs
regulate stem cell homeostasis rather than influencing
differentiation to any particular phenotype. Importantly,
many of the miRNAs that were identified in this study
have also been shown to be dysregulated in acute myeloid
leukemia (AML). For example, miR-125b expression in
bone marrow cells led to a myeloproliferative disorder that
could progress to aggressive myeloid leukemia [30]. Along
the same line, miR-196b was shown to be overexpressed
specifically in the majority of patients with mixed lineage
leukemia (MLL), but not in other types of leukemia [31].
Moreover, with the exception of miR-193b, all of the
miRNAs that were shown to be enriched in mouse HSCs
also showed significant enrichment in CD34+ progenitorsderived from human cord blood compared with mature
CD34− cells [30]. Early human hematopoietic cells are
characterized by high expression levels of the CD133 sur-
face marker, and can generate CD34+ progenitors, which
in turn can differentiate to all hematopoietic lineages
[32,33]. Human CD133+ cells were analyzed in a
combined miRNA-mRNA expression profile to identify
miRNAs that might contribute to the maintenance of the
HSC ‘stemness’ [34]. Among the miRNAs identified,
target analysis revealed that miR-29a downregulated the
expression of the actin binding protein TMP1, as well as
of FZD5, a receptor acting in the Wnt-signaling pathway
[34]. Interestingly, MiR-29a was also shown to be involved
in the regulation of early hematopoiesis and myeloid
commitment in the mouse system. MiR-29a was highly
expressed in early progenitors where it likely contributed
to the maintenance of the undifferentiated status,
while it was downregulated during differentiation [35].
Accordingly, ectopic expression of miR-29a in mouse
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bilities of myeloid precursors, biased myelopoiesis and
development of a myeloproliferative disorder that could
progress to AML. Highlighting its importance as a
regulator of self-renewal and proper myelopoiesis, not
only miR-29a overexpression in the mouse induced an
AML-like disease, but miR-29a was also found strongly
overexpressed in patients with AML [35].
While most of the miRNAs discussed so far were
mainly found to be involved in somehow maintaining
the self-renewal feature typical of stem cells, other
miRNAs instead favored HSC differentiation to more
committed cell types. MiRNA expression profiles from
human CD34+ hematopoietic progenitors and in vitro
differentiated erythroblasts, megakaryoblasts, monoblasts
and myeloblast precursors showed a specific upregulation
of miR-299-5p in megakaryoblasts together with the
downregulation of its putative target genes [36]. Accord-
ingly, forced expression or inhibition of miR-299-5p in
CD34+ cells altered the colony formation capacity of these
cells, modulating megakaryocytic-granulocytic differen-
tiation versus erythroid-monocytic commitment [36].
MiR-221 and miR-222 were also involved in the regulation
of both the early and late stages of erythropoiesis: CD34+
cells transfected with either miRNA mimics or lentiviruses
to force expression of these two miRNAs showed inhib-
ition of proliferation and accelerated differentiation to
the erythropoietic lineage through downregulation of
one of their target, c-Kit [37]. In order to provide a more
complete scenario of the regulation of hematopoietic
differentiation by miRNAs, Petriv et al. developed a high-
throughput technique that combined microfluidics with
the sensitivity and specificity of qRT-PCR, allowing
miRNA profiling on limited cell numbers or even at a
single cell level [38]. Using this technique the authors
were able to analyze 27 different cell populations, includ-
ing ES cells, early hematopoietic precursors, CMP, CLP,
GMP, MEP as well as mature cells representative of all
lineages. Interestingly, reconstruction of a hematopoietic
hierarchical tree based on the miRNA expression pattern
grouped the 27 cell types investigated into six main
branches: stem cells and multipotent progenitors, lymph-
oid cells, and finally four different major branches of
myeloid cells. Several miRNAs were then found to change
in expression at distinct nodes. In particular, the most
differentially expressed miRNAs between stem cells and
progenitors relative to the more mature populations
included miR-125b, miR-196a/b, miR-130a, let-7d,
miR-148b and miR-351. Similarly, changes in expression
of a number of other miRNAs distinguished CMPs from
CLPs or CMPs from more committed progenitors [38].
Despite the fact that a number of miRNAs have been
described to be specifically expressed in various steps
during the differentiation process of early hematopoieticprogenitors, the targets that are regulated by these miR-
NAs and their overall biological impact on lineage com-
mitment and HSCs homeostasis remain for the most part
to be uncovered, and further analysis will be required to
completely dissect the molecular network regulated by
miRNAs in hematopoietic differentiation.
Innate immunity
The innate immune system is the first responder
towards invading pathogens. Innate immune cells include
dendritic cells, granulocytes, monocytes/macrophages
and mast cells, which are all bone marrow-derived.
Granulocytes are short-lived cells that include neutro-
phils, basophils and eosinophils, which can be distin-
guished by their staining properties, surface markers and
functions. MiRNAs have been shown to regulate a
number of aspects of innate cell differentiation and func-
tion as well as of innate responses (for a recent review on
the topic see [39]). A key miRNA that was shown to regu-
late granulocytic differentiation and function is miR-223,
which showed a pattern of expression highly lineage-
specific. Indeed, miR-223 was shown to be expressed at
low levels in HSCs and CMPs, and to be steadily upregu-
lated during differentiation to granulocytes and repressed
during differentiation to the alternative monocytic fate
[40]. Interestingly, lack of miR-223 in mice resulted in an
expanded granulocytic compartment due to an increased
number of progenitors. The transcription factor Mef2c
was shown to be a target for miR-223 in these mice, and
genetic ablation of this transcription factor corrected
the phenotype induced by the absence of miR-223. In
addition, granulocytes that developed in miR-223-deleted
animals showed terminal maturation and increased sensi-
tivity to activating stimuli, to the point that mice devel-
oped neutrophil-mediated disease with spontaneous lung
pathology and excessive tissue damage after challenge
[40]. Of note, expression of miR-223 in human acute pro-
myelocytic leukemia cells led to enhanced differentiation
in response to treatment with retinoic acids [41,42]. Des-
pite some differences in findings that can be due at least
in part to the different systems used, miR-223 has un-
doubtedly emerged as an important regulator of both the
generation and function of granulocytic cells, by modu-
lating their differentiation as well as their sensitivity to
activating stimuli [40]. Highlighting the overall import-
ance of the miRNA pathway in regulating myelopoiesis,
deletion of Dicer specifically in myeloid-committed
progenitors led to defective myeloid development, with
reduced differentiation of these cells and regained self-
renewal potential [43].
Macrophages are long-lived, tissue-resident cells derived
from circulating monocytes. They are remarkable phago-
cytic cells committed to the engulfment and elimination
of invading microorganisms, and they can also contribute
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leasing inflammatory and signaling molecules. MiR-17-5p,
miR-20a and miR-106a were all implicated in the diffe-
rentiation of monocytes. Specifically, these miRNAs were
shown to act in a molecular circuitry with the transcrip-
tion factors AML1 (Runx1) to regulate expression of the
macrophage-colony stimulating factor receptor (M-CSFR)
and consequently modulating monocytic differentiation
[44]. The transcription factor AML1 is crucial for the
development of the hematopoietic system, as shown by
the fact that deletion of the Aml1 gene in mice is embry-
onically lethal due to failed hematopoiesis [45]. During
monocytic differentiation, AML1 was shown to be upreg-
ulated at the protein but not mRNA level, concomitantly
with declined expression of miR-17-5p, miR-20a and
miR-106a [44]. Reduced expression of these miRNAs
unblocked translation of AML1, which in turn could
inhibit transcription of these miRNAs in a negative
feedback loop, finally allowing cell differentiation [44].
The importance of carefully tuning AML1 expression is
also highlighted by the fact that in myeloid leukemias the
fusion protein AML1-ETO results in altered transcrip-
tional activity of AML1 [46-50], leading to the expansion
of immature cells in a scenario that resembles overexpres-
sion of miR-17-5p, miR-20a and miR-106a [44]. Highlight-
ing the importance of the miR-17 ~92 cluster in cancer
and leukemia, a number of studies have shown that this
miRNA cluster (consisting of miR-17-5p, miR-18a, miR-
19a, miR-19b, miR-20a, and miR-92a) is frequently over-
expressed in several solid and lymphoid malignancies [51],
and forced expression of this locus led to lymphoprolifera-
tion [52-54]. Interestingly, deletion of the miR-17 ~92
cluster is associated with altered embryonic development
and death [55], and dyregulation of a number of targets of
this cluster (including the tumor suppressor PTEN and
the proapoptotic protein Bim [52]) is thought to contrib-
ute to tumorigenesis.
Several miRNAs are involved not only in monocytic
differentiation but also in macrophage polarization. Mac-
rophages can be sub-divided into different phenotypically
distinct subpopulations: two of these populations include
classically activated or M1 and alternatively activated or
M2 macrophages, which are characterized by distinct
surface markers, cytokine production capabilities, differ-
entiation requirements and functional properties [56].
One of the miRNAs shown to be potentially involved in
regulating the balance between M1 and M2 differentiation
is miR-155 [57]. MiR-155 was shown to be upregulated in
macrophages upon LPS treatment [58], and in human
monocytes, it was shown to directly target IL-13Rα1, the
receptor for IL-13, a critical cytokine for the balance
between M1 and M2 macrophage polarization [57].
MiR-155 expression led to reduced IL-13-dependent
STAT6 phosphorylation and changed the mRNA expressionprofile of several IL-13/STAT6-dependent genes. Along
the same line, IL-10, which is an anti-inflammatory cyto-
kine also known to be important in regulating M1/M2
polarization, was shown to inhibit LPS-dependent upre-
gulation of miR-155, further suggesting a role for this
miRNA in the modulation of the balance between differ-
ently polarized macrophages and more in general in the
regulation of inflammation [56,59].
Dendritic cells (DC) are the most specialized and potent
antigen presenting cells (APCs) of the immune system, es-
sential to induce adaptive immunity. These tissue-resident
cells can be subdivided in different subsets, including
conventional DCs (cDC) and plasmacytoid DCs (pDCs).
The expression of miRNAs during DC differentiation
from monocytes was extensively studied using microarray
analysis [60-62]. For example, Lu et al. analyzed the
miRNA profile during development of immature (imDC)
and mature DCs from monocytes [62]. Specifically, miR-
155 and miR-221 regulated human DC differentiation by
modulating proliferation and cell death. MiR-221 and
miR-155 expression was relatively low in monocytes,
which expressed higher levels of the cell-cycle inhibitor
p27Kip1. Upon induction of differentiation, miR-221 was
upregulated with a concomitant reduction of its target
p27Kip1, driving DC maturation. During maturation DCs
downregulated miR-221 and upregulated miR-155, result-
ing in accumulation of p27Kip1 and induction of IL12p70,
contributing to the regulation of apoptosis and promoting
terminal differentiation [62]. MiR-221 and miR-222
were also shown to be expressed at higher levels in
cDCs compared to pDCs, and inhibition of these miRNAs
decreased the number of cDCs and favored pDCs accu-
mulation [63].
MiR-155 is another miRNA important for DC functions:
it is contained within the noncoding B cell integration clus-
ter (bic) gene, and its importance in DC differentiation and
function is highlighted by the fact that DCs lacking bic/
miR-155 exhibited reduced functionality, with a strong im-
pairment in their ability to stimulate T cells [64]. As for the
mechanism of action of miR-155, microarray and functional
experiments revealed that one of the key roles of miR-155
in DCs is the silencing of the transcription factor c-Fos,
and cells with dysregulated c-Fos expression phenocopied
the lack of miR-155 [65]. Interestingly, a role for the less
abundant passenger strand of miR-155, miR-155*, was also
identified for pDC activation upon TLR7 stimulation, and
although miR-155 and miR-155* are processed from a
single precursor, they appeared to have opposing effects
on the production of type I interferons from pDCs [66].
Adaptive immunity: B cell maturation and germinal
center responses
The adaptive immune system is composed by highly
specialized cells (B and T lymphocytes) that are able to
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inate pathogens and finally develop an immunological
memory that can quickly respond to a subsequent inva-
sion from the same pathogen. B lymphocytes respond to
antigen recognition by producing a wide spectrum of
antibodies. The molecular network that leads to proper
B cell development must be finely orchestrated, and
includes miRNA-dependent posttranscriptional regula-
tion. Indeed, the overall impairment of miRNA biogen-
esis induced by Dicer ablation in B cell precursors
caused a block of B cell differentiation in the transition
from pro- to pre-B cells [67]. Gene expression profiles of
Dicer-deficient pro-B cells revealed a specific miR-17 ~92
signature in the 3′UTRs of the upregulated genes,
highlighting the importance of this particular cluster of
miRNAs in B cell differentiation [67]. Indeed, mice in
which miR-17 ~92 were overexpressed developed spon-
taneous lymphoproliferative disease and autoimmunity
[52]. Not only the expression of miR-17 ~92 is important
to regulate survival of early B cell progenitors in a cell-
autonomous manner, but these miRNAs also regulate B
cell responses by controlling differentiation of follicular
helper T lymphocytes (TFH). This subset of T helper lym-
phocytes is crucial to provide signals to B cells to develop
appropriate antibody responses, and genetic deletion of
miR-17 ~92 led to substantially compromised differenti-
ation of TFH cells and consequently to reduced antibody
responses to infection [68,69].
Consistent with a crucial role of miRNAs in regulating
B cell functions, the formation of germinal centers in
secondary lymphoid organs was drastically compromised
in the absence of Dicer: Dicer1fl/flAicdaCre/+ mice, in which
Dicer ablation is under the control of the activation-
induced cytidine deaminase (AID) promoter and therefore
occurred only in activated B cells, showed impaired class-
switch recombination as well as compromised B cell
memory formation [70]. In addition, the selective ablation
of another fundamental component of the RISC complex,
Argonaute 2, affected pre-B cell differentiation as well as
maturation of erythroid precursors [71]. Taken together,
these studies demonstrated the critical role of Dicer and
miRNAs in B cell differentiation both in the bone marrow
and in the periphery.
As for the role of individual miRNAs in B cell differenti-
ation and function, one example is provided by miR-150
that is normally expressed at low levels in HSCs, and is
instead upregulated during differentiation. Its ectopic
expression in HSCs was associated with a severe impair-
ment in the formation of mature B cells and with the
block of the transition from the pro- to pre-B stage [72].
In particular, B cell progenitors deleted for miR-150
showed impaired B cell responses and differentiation
defects due to the dysregulation of c-Myb, a target
for miR-150 known to play a critical role in multiplesteps of lymphocyte development [73]. The pro- to pre-B
cell transition is also regulated by miR-34a through in-
hibition of the transcription factor Foxp1 [74]. The consti-
tutive expression of miR-34a induced a partial block
in B cell development while its knockdown resulted
in increased number of mature B cells in the bone
marrow, and knockdown of Foxp1 induced a phenotype
that resembled the one observed upon overexpression of
miR-34a [74]. Additionally, miR-34a itself was shown to
be induced at a transcriptional level by the transcription
factor p53, and accordingly, mice in which p53 was
deleted showed accumulation of pro-B cells [75-78]. p53
may therefore regulate B cell development at least in part
through the upregulation of miR-34a and consequent in-
hibition of Foxp1 [74]. Finally, further studies demon-
strated the involvement of miRNAs also in the latest
stages of B cell maturation. Experiments using genetic
ablation and transgenic approaches to analyze the effect
of altered miR-155 expression revealed impaired germinal
center reactions in the context of T cell-dependent anti-
body responses as well as altered cytokine production
[64,79]. Moreover, B cells lacking miR-155 generated
reduced extrafollicular and germinal centre responses
upon stimulation with both thymus-dependent and -inde-
pendent antigens, which correlated with the reduced
number of rearranged IgG antibodies [80]. Interestingly,
miR-155–deficient B cells showed upregulation of the
transcription factor PU.1, whereas PU.1 overexpression in
wild-type B cells resulted in reduction of IgG1-switched
cells, suggesting that miR-155 directly regulates class-
switching recombination in secondary lymphoid organs
through PU.1 expression [80]. AID was also shown to be a
target for miR-155 in B cells [81,82]. AID is required for
immunoglobulin gene diversification through somatic
hypermutation (SHM) and class-switch recombination
(CSR), and disruption of miR-155–dependent AID regula-
tion led to quantitative and temporal dysregulation of AID
expression resulting in altered affinity maturation and
CSR, but also in a high degree of chromosomal transloca-
tions [81,82]. Taken together these results implicate post-
transcriptional regulation of gene expression mediated by
miRNAs in all stages of B cell differentiation, activation
and memory formation.
Adaptive immunity: T cell differentiation and polarization
The stages of development of T lymphocytes into func-
tional cells are characterized by the expression not only
of the T cell receptor (TCR) and associated molecules,
which allow antigen recognition and signal transduction
within the cell, but also by the expression of the core-
ceptor molecules CD4 and CD8. CD4 and CD8 double-
negative (DN) cells are the early T cell progenitors,
which differentiate into CD4/CD8 double-positive (DP)
cells and then in CD4 or CD8 single-positive (SP) cells.
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and CD25, DN thymocytes can be further divided into
four stages (DN1-4) following the order of appearance
during differentiation. In order to investigate the bio-
logical function of the miRNA pathway in T lymphocyte
development, the selective ablation of the Dicer1 gene in
DP thymocytes was performed using a Cre recombinase
under the control of the CD4 promoter [83]. Upon
Dicer1 deletion, a severe block in the development of
peripheral CD8 T cells was observed, as well as a
smaller, but still significant, decrease of CD4 T cells in
the spleen and lymph nodes. Further characterization of
these CD4 T lymphocytes showed increased levels of
apoptosis, defective proliferation and aberrant cytokine
production, indicating that miRNAs are essential for the
proper maturation and function of T lymphocytes in the
periphery [83]. Importantly, when Dicer1 was selectively
ablated earlier during thymocyte development at the
DN3 stage using an lck-Cre transgene, numbers of αβ T
cells were reduced, correlating with an increased suscep-
tibility to cell death of these cells, while the CD4/CD8
lineage choice appeared largely intact [84]. While Dicer
was shown to regulate centromeric silencing, affecting
telomere length homeostasis as well as de novo methyla-
tion in ES cells [16], conditional ablation of Dicer1 in
DN3-stage thymocytes did not appear to be required
for epigenetic regulation of these cells. Indeed, the
transcriptional silencing at pericentromeric satellite
sequences, DNA methylation and X chromosome in-
activation in female cells, as well as the stable silencing of
the Tdt gene, which is involved in TCR rearrangement,
were globally not affected in Dicer1-deleted thymocytes,
indicating that the epigenetic marks established during
differentiation of T cells are maintained independently
from Dicer expression [84].
Since Dicer was shown to be involved in several
aspects of the hematopoietic differentiation as well as
lymphocyte development, it is not surprising that the
overall impairment of the miRNA biogenesis could
interfere also with CD4 T helper (Th) cell polarization,
as well as with the differentiation of regulatory T cells
(Tregs) (see Refs. [85,86] for recent reviews on the
topic). Gene-deleted mouse models of either Drosha or
Dicer in the T cell compartment resulted in spontaneous
T cell activation, inflammatory disease and premature
death due to compromised Treg differentiation and re-
duced suppressive activity, recapitulating the phenotypes
observed in the absence of Foxp3 [87,88]. Importantly,
Dicer and Drosha deficiencies were also shown to alter
T lymphocytes polarization. Th1 cells are characterized
by strong IFN-γ production, whereas Th2 responses are
mainly based on IL-4 production. Dicer-deficient CD4 T
cells could not repress IFN-γ production and continued
to produce IFN-γ even after two consecutive rounds ofactivation under Th2 conditions, indicating that Dicer is
required for repression of the Th1 genetic program [83].
In addition, the vast majority of Dicer-deficient Th2 cells
restimulated and further cultured under Th1 polarizing
conditions regained IFN-γ production, further indicating
that Dicer is required to repress the Th1 genetic pro-
gram and also suggesting that Dicer deficiency may
impair stable Th2 commitment [83]. Importantly, a simi-
lar phenotype was observed in Drosha-deficient as well
as in DGCR8-deficient T cells [87,89], indicating that the
lack of miRNAs in T cells determines a bias towards
IFN-γ production and reduced proliferation and survival
after stimulation [89]. In order to identify individual
miRNAs primarily responsible for these observed phe-
notypes, miRNAs were individually screened for their
capacity to correct aberrant IFN-γ production in the
absence of DGCR8 [89]. Using this method, miR-29a
and miR-29b were identified as suppressors of the Th1
fate. In particular, transfection of both miR-29a and
miR-29b in DGCR8-deficient T cells induced a reduction
in IFN-γ production in a dose-dependent manner and
the same phenotype was observed even in conditions
that strongly promoted Th1 cell differentiation. Interest-
ingly, these miRNAs had no significant effect on the
total frequency of IL-4– or IL-2–producing cells and
they did not affect cell proliferation or viability, indicat-
ing that the effect of miR-29a and miR-29b goes through
specific regulation of IFN-γ production. Indeed, both
T-bet and Eomes, transcription factors critical for
IFN-γ production, were identified as direct targets of
miR-29a/b [89]. Along the same line, infection of wild-
type mice with intracellular bacteria induced downregula-
tion of miR-29a/b in CD4 and CD8 T cells, with enhanced
IFN-γ production and consequent elimination of the
pathogen [90]. Transgenic mice engeneered to express a
miR-29 ‘sponge’ that competed with endogenous miR-29
targets, showed enhanced Th1 responses and greater
resistance to infection [90].
In a hallmark example of a role of miRNAs in regulat-
ing TCR signaling, Li et al. identified miR-181a as an
intrinsic modulator of T cell sensitivity to peptide anti-
gens [91]. MiR-181a was shown to be expressed at high
levels in the earliest stages of T cell differentiation,
namely in DN1-3 cell populations, and to drop dramat-
ically in DN4 cells, as well as in DP and SP thymocytes,
indicating that this miRNA may play a role in T cell
maturation [91]. Further experiments demonstrated that
miR-181a regulates thymic positive and negative selec-
tion through the modulation of TCR signaling strength,
at least in part by downregulating a number of phospha-
tases, and therefore leading to elevated levels of phosphor-
ylated signaling proteins and to an overall reduction of the
TCR activation threshold [91]. Indeed, the TCR strength
of signal is regulated by the phosphorylation state of
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T cell activation. The tyrosine phosphatases SHP-2,
PTPN22 and the ERK-specific phosphatases DUSP5 and
DUSP6 were all shown to contain miR-181a binding sites
and to be specifically repressed by miR-181a. As a conse-
quence, T cells overexpressing miR-181a showed signifi-
cantly higher basal levels of phosphorylated ERK (pERK)
compared to control cells, with both the maximum peak
of ERK phosphorylation and the kinetic of dephosphoryla-
tion being altered in presence of miR-181a. These results
indicate that miR-181a expression is important to main-
tain high levels of pERK through inhibition of phospha-
tases, thus reducing the activation threshold to peptide
antigens [91].
In the final stages of T lymphocyte maturation, some
of the activated cells acquire a long-lived memory
phenotype that allows a more rapid and effective re-
sponse to pathogens that have been previously encoun-
tered. MiR-146a was shown to be induced upon TCR
stimulation to levels that directly correlated with the
strength of TCR signaling [92]. Importantly, this miRNA
was shown to be involved in effector and memory CD8
responses, with mice lacking miR-146a responding more
vigorously and persistently to peptide antigens, in line
with a role for this miRNA as a general negative regulator
of the immune response, but possibly also as a modulator
of the TCR signaling threshold and memory formation
[92-94]. It would be tempting to speculate that, resem-
bling the effect of miR-181a in regulating the TCR signal
strength in thymocytes, miR-146a may have a similar role
in the periphery by modulating the activation of NF-kB
upon TCR recognition of the antigen. Overall, although
work remains to be done to elucidate the details of regula-
tion, data from the past several years leave no doubts
about an important role for miRNAs in T cell develop-
ment, differentiation to the appropriate subsets, establish-
ment of immunological memory and the maintenance of
homeostasis in the periphery [86].
Conclusions
MiRNAs are fundamental regulators of hematopoiesis,
critically implicated in regulating both the maintenance
of the ‘stemness’ of the early progenitors and the various
stages of differentiation to mature cells. While their
overall role in these processes is quite established, we
still need to elucidate the function of individual miRNAs
in distinct cell types or developmental stages, especially
since the effect of a given miRNA may be exquisitely
dependent on the cellular context in which it is
expressed. Indeed, since what eventually matters for the
regulation of a miRNA target is the concentration of the
given miRNA relative to that of its target, factors like
miRNA abundance and stability, ability to participate in
multiple rounds of targeting, as well as expression ofcell-specific mRNA targets, will all influence miRNA
networks and miRNA-transcription factor circuits (dis-
cussed in [95]). Depending on all of the abovementioned
factors, one could easily envision situations in which the
same miRNA may act on different targets and lead to
different outcomes in different cellular contexts. More-
over, miRNAs emerged as an important component of
the many checks and balances required to keep the
immune system from getting out of control, potentially
leading to tissue damage and disease. Indeed, the im-
portance of miRNAs in these processes is emphasized by
their aberrant expression in pathologic conditions such as
autoimmune disease and cancer [96-100]. Since a chronic
dysregulation of miRNA expression may lead to aberrant
differentiation, uncontrolled proliferation and break of im-
munological tolerance, understanding miRNA-mediated
control of gene expression could provide innovative
strategies for treatment of hematopoietic malignancies
and other diseases. In one potentially useful therapeutic
application of miRNAs, miR-150 was identified as a
miRNA responsible for reduced hematopoietic recovery
following chemotherapy-induced suppression of periph-
eral blood parameters [101]. These data further highlights
how manipulation of miRNA expression may become
important in the future in a variety of clinical and more
translational settings.
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